Satellos Bioscience (TSE:MSCL) has released an update.
Satellos Bioscience has made a significant stride with their proprietary drug SAT-3247, receiving the U.S. FDA Rare Pediatric Disease and Orphan Drug Designations for the treatment of Duchenne muscular dystrophy (DMD). This novel oral small molecule aims to regenerate skeletal muscle lost due to DMD, with a Phase 1 clinical trial expected to start in Q3 2024. The designations could provide multiple regulatory and financial incentives, boosting the drug’s potential market success.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
